Morrisville, North Carolina (ots/PRNewswire) – – Daten von Reveal(R) könnten neuen Standard der Überwachung setzen nContact, Inc., führender Innovator bei Geräten für die epikardiale Ablation, hat heute bekannt gegeben, dass Daten, die auf dem 17. internationalen jährlichen Fachsymposium zum Thema Vorhofflimmern in Boston (17. Annual International Boston Atrial Fibrillation Symposium) von Ärzten in zwei Vorträgen [...]
Tag Archive > Atrial Fibrillation
Pan-European Stroke Prevention in Atrial Fibrillation Registry – PREFER in AF – Enrols First Patient
Munich (ots/PRNewswire) – – For European Media Only – Collection of real life data from 5,000 atrial fibrillation patients (AF) across seven countries will generate invaluable insights into one of Europe’s leading causes of stroke(1,2) — Daiichi Sankyo Europe GmbH today announced the enrolment of the first patient into the PREvention oF thromboembolic events – [...]
nContacts Technologie zur kardialen Ablation wird im Rahmen zweier Vorträge auf dem Atrial Fibrillation Symposium 2012 vorgestellt
Morrisville, North Carolina (ots/PRNewswire) – nContact, Inc., der führende Wegbereiter von Geräten zur epikardialen Ablation, gab heute bekannt, dass Fachärzte die Technologie des Unternehmens im Rahmen zweier Fachvorträge auf dem 17. internationalen jährlichen Fachsymposium zum Thema Vorhofflimmern in Boston (Annual International Boston Atrial Fibrillation Symposium) vorstellen werden. Die Veranstaltung findet vom 12. bis 14. Januar [...]
Leading Heart Advocates Launch AFib Task Force in Brussels
Brussels, November 29 (ots/PRNewswire) – Leaders from policy, medical and patient environments address European heart health in joint approach In the European Parliament today, Cristian Busoi MEP, along with European heart advocates, announced the launch of their new AFib Task Force. The Task Force has been established to help address the increasing challenge posed by [...]
Studie in sechs Zentren zu chronischem Vorhofflimmern belegt Relevanz eines intraoperativen Leitungsblocknachweises bei der Radiofrequenzablation
Morrisville, North Carolina (ots/PRNewswire) – nContact, Inc. (nContact), führender Hersteller von Geräten für die minimal-invasive epikardiale Ablation, bezieht sich auf einen im European Journal of Cardio-thoracic Surgery veröffentlichten Artikel, der die Bedeutung eines lückenlosen epikardialen Läsionsmusters in Kombination mit Diagnostik zum Leitungsblocknachweis bei der Radiofrequenzablation zur erfolgreichen Behandlung von persistierendem und langanhaltendem persistierenden Vorhofflimmern (AF [...]
EANS-Adhoc: LIFEWATCH TEAMS WITH UNITEDHEALTHCARE, THE LARGEST HEALTHCARE INSURER IN THE UNITED STATES, AS A PREFERRED NATIONAL PROVIDER OF CARDIAC MONITORING SERVICES TO REDUCE PATIENT COSTS (with document)
——————————————————————————– ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. ——————————————————————————– Company Information/LifeWatch AG 21.02.2011 Neuhausen am Rheinfall/Switzerland und Rosemont/Illinois – LifeWatch AG (SIX Swiss Exchange: LIFE), the leading provider of wireless telemedicine, today announces an initiative with UnitedHealthcare Insurance [...]
The World Heart Federation, sanofi-aventis and Boehringer Ingelheim Announce Collaboration on Worldwide AF Awareness Campaign
Geneva (ots/PRNewswire) – The World Heart Federation, sanofi-aventis and Boehringer Ingelheim have announced their collaboration on the AF AWARE (Atrial Fibrillation AWareness And Risk Education) campaign today, to raise awareness of atrial fibrillation (AF) and its links to severe consequences including cardiovascular (CV) mortality, stroke and CV hospitalizations. The campaign aims to promote education around [...]
Sanofi-aventis Partners in European Atrial Fibrillation Research Consortium
Paris, November 5 (ots/PRNewswire) – Sanofi-aventis announced today that it is a partner in a new multidisciplinary atrial fibrillation research consortium, the “European Network for Translational research in Atrial Fibrillation” (EUTRAF), which has been awarded a EUR12 million grant to engage in atrial fibrillation (AF) research. The European consortium is commencing a five-year research project [...]
DAIICHI SANKYO Announces Enrollment in the Two Largest Single Phase III Trials so far for the Prevention of Stroke in AF and for the Treatment of VTE is Proceeding as Planned
Stockholm (ots/PRNewswire) – DAIICHI SANKYO announced today that the ongoing trials ENGAGE AF-TIMI 48 (The Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation) and HOKUSAI VTE with their investigational factor Xa inhibitor edoxaban are enrolling in accordance to plan. The projected recruitment of ENGAGE AF-TIMI 48 and HOKUSAI VTE are 20,500 and 7,500 [...]
Multaq(R) First-line Option in New 2010 ESC Guidelines for the Management of Atrial Fibrillation
Paris, August 29, 2010 (ots/PRNewswire) – Sanofi aventis announced today that the European Society of Cardiology (ESC) 2010 new Guidelines for the Management of Atrial Fibrillation (AF) have been released and recommend that Multaq(R) (dronedarone) should be used for maintenance of sinus rhythm as a first-line treatment option in all patients with paroxysmal and persistent [...]
Survey Reveals Many are Ignoring Basic Measures to Check for no.1 Heart Killer Disorder in Europe
STRATFORD- UPON-AVON, England, June 7, 2010 (ots/PRNewswire) – – On World Heart Rhythm Week, Arrhythmia Alliance Launches ‘Know Your Pulse’ Campaign to Raise Awareness of the Importance of Pulse Checking to Keep Cardiac Conditions Under Control Arrhythmia Alliance, the Heart Rhythm Charity, announced today the results of a survey conducted in Europe that showed a [...]
Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent Atrial Fibrillation
Paris, May 12, 2010 (ots/PRNewswire) – Sanofi-aventis announced today the initiation of a multinational, randomized, double-blind Phase IIIb trial, PALLAS, to assess the potential clinical benefit of Multaq(R) (dronedarone) in over 10,000 patients with permanent atrial fibrillation (AF) to reduce major adverse cardiovascular events. The announcement was made during Heart Rhythm 2010, the Heart Rhythm [...]
EANS-Adhoc: LifeWatch kündigt neues "AF TeleClinic" Programm an
——————————————————————————– Ad-hoc-Mitteilung übermittelt durch euro adhoc mit dem Ziel einer europaweiten Verbreitung. Für den Inhalt ist der Emittent verantwortlich. ——————————————————————————– Neue Produkte/LifeWatch AG 11.05.2010 Erstes Angebot aus einer neuen Reihe von behandlungsspezifischen Programmen Chicago, IL / USA, 11. Mai 2010 – LifeWatch Services, Inc., eine Tochtergesellschaft von LifeWach AG (SIX Swiss Exchange: LIFE), stellt diese [...]
EANS-Adhoc: LifeWatch Announces the World’s First iPad ECG Report Viewers
——————————————————————————– ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. ——————————————————————————– New Products/LifeWatch AG 11.05.2010 Chicago, IL / USA May 11 2010 -LifeWatch Services, Inc., a subsidiary of LifeWatch AG (SIX Swiss Exchange: LIFE), will announce the launch of their [...]
Sanofi-aventis: Multaq(R) Receives Positive Recommendation by NICE in New Appraisal Consultation Document
Paris, March 30, 2010 (ots/PRNewswire) – Sanofi-aventis announced today that the National Institute for Health and Clinical Excellence (NICE) in England and Wales, has just published a new appraisal consultation document (ACD)[1] for Multaq(R) (dronedarone) indicating its intention to recommend Multaq(R) use for the management of patients with atrial fibrillation (AF). The NICE appraisal committee’s [...]
